Model of Liver Fibrosis Induction by Thioacetamide in Rats for Regenerative Therapy Studies.

IF 2.6 4区 医学 Q3 CELL BIOLOGY
Analytical Cellular Pathology Pub Date : 2022-11-12 eCollection Date: 2022-01-01 DOI:10.1155/2022/2841894
Nathaly Enciso, José Amiel, Fredy Fabián-Domínguez, Jhon Pando, Nancy Rojas, Carlos Cisneros-Huamaní, Ernesto Nava, Javier Enciso
{"title":"Model of Liver Fibrosis Induction by Thioacetamide in Rats for Regenerative Therapy Studies.","authors":"Nathaly Enciso,&nbsp;José Amiel,&nbsp;Fredy Fabián-Domínguez,&nbsp;Jhon Pando,&nbsp;Nancy Rojas,&nbsp;Carlos Cisneros-Huamaní,&nbsp;Ernesto Nava,&nbsp;Javier Enciso","doi":"10.1155/2022/2841894","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatic fibrosis is caused by chronic injury due to toxic, infectious, or metabolic causes, and it may progress to cirrhosis and hepatocellular carcinoma. There is currently no antifibrotic therapy authorized for human use; however, there are promising studies using cell therapies. There are also no animal models that exactly reproduce human liver fibrosis that can be used to better understand the mechanisms of its regression and identify new targets for treatment and therapeutic approaches. On the other hand, mesenchymal stem cells (MSC) have experimentally demonstrated fibrosis regression effects, but it is necessary to have an animal model of advanced liver fibrosis to evaluate the effect of these cells. The aim of this work was to establish a protocol for the induction of advanced liver fibrosis in rats using thioacetamide (TAA), which will allow us to perform trials using MSC as a possible therapy for fibrosis regression. For this purpose, we selected 24 female rats and grouped them into three experimental groups: the control group (G-I) without treatment and groups II (G-II) and III (G-III) that received TAA by intraperitoneal injection for 24 weeks. Then, 1 × 106/kg adipose mesenchymal stem cells (ASCs) were infused intravenously. Groups G-I and G-II were sacrificed 7 days after the last dose of ASC, and G-III was sacrificed 8 weeks after the last ASC infusion, all with xylazine/ketamine (40 mg/kg). The protocol used in this work established a model of advanced hepatic fibrosis as corroborated by METAVIR tests of the histological lesions; by the high levels of the markers <i>α</i>-SMA, CD68, and collagen type I; by functional alterations due to elevated markers of the hepatic lesions; and by alterations of the leukocytes, lymphocytes, and platelets. Finally, transplanted cells in the fibrous liver were detected. We conclude that TAA applied using the protocol introduced in this study induces a good model of advanced liver fibrosis in rats.</p>","PeriodicalId":49326,"journal":{"name":"Analytical Cellular Pathology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2022-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675604/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Analytical Cellular Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2022/2841894","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Hepatic fibrosis is caused by chronic injury due to toxic, infectious, or metabolic causes, and it may progress to cirrhosis and hepatocellular carcinoma. There is currently no antifibrotic therapy authorized for human use; however, there are promising studies using cell therapies. There are also no animal models that exactly reproduce human liver fibrosis that can be used to better understand the mechanisms of its regression and identify new targets for treatment and therapeutic approaches. On the other hand, mesenchymal stem cells (MSC) have experimentally demonstrated fibrosis regression effects, but it is necessary to have an animal model of advanced liver fibrosis to evaluate the effect of these cells. The aim of this work was to establish a protocol for the induction of advanced liver fibrosis in rats using thioacetamide (TAA), which will allow us to perform trials using MSC as a possible therapy for fibrosis regression. For this purpose, we selected 24 female rats and grouped them into three experimental groups: the control group (G-I) without treatment and groups II (G-II) and III (G-III) that received TAA by intraperitoneal injection for 24 weeks. Then, 1 × 106/kg adipose mesenchymal stem cells (ASCs) were infused intravenously. Groups G-I and G-II were sacrificed 7 days after the last dose of ASC, and G-III was sacrificed 8 weeks after the last ASC infusion, all with xylazine/ketamine (40 mg/kg). The protocol used in this work established a model of advanced hepatic fibrosis as corroborated by METAVIR tests of the histological lesions; by the high levels of the markers α-SMA, CD68, and collagen type I; by functional alterations due to elevated markers of the hepatic lesions; and by alterations of the leukocytes, lymphocytes, and platelets. Finally, transplanted cells in the fibrous liver were detected. We conclude that TAA applied using the protocol introduced in this study induces a good model of advanced liver fibrosis in rats.

Abstract Image

Abstract Image

Abstract Image

硫乙酰胺诱导大鼠肝纤维化再生治疗模型的建立。
肝纤维化是由毒性、感染性或代谢性原因引起的慢性损伤引起的,并可能发展为肝硬化和肝细胞癌。目前还没有批准用于人类的抗纤维化治疗;然而,使用细胞疗法的研究也很有前景。也没有动物模型可以精确地重现人类肝纤维化,从而更好地理解其消退机制,并确定新的治疗靶点和治疗方法。另一方面,间充质干细胞(mesenchymal stem cells, MSC)在实验中已经证明了纤维化的消退作用,但需要建立晚期肝纤维化动物模型来评估这些细胞的作用。这项工作的目的是建立一个使用硫乙酰胺(TAA)诱导大鼠晚期肝纤维化的方案,这将使我们能够使用MSC作为纤维化消退的可能治疗方法进行试验。为此,我们选择24只雌性大鼠,将其分为3个实验组:未经治疗的对照组(G-I组)和腹腔注射TAA 24周的II组(G-II组)和III组(G-III组)。然后静脉输注1 × 106/kg脂肪间充质干细胞(ASCs)。G-I组和G-II组在最后一次ASC输注后7天处死,G-III组在最后一次ASC输注后8周处死,均给予噻嗪/氯胺酮(40 mg/kg)。这项工作中使用的方案建立了晚期肝纤维化模型,经METAVIR组织学病变试验证实;α-SMA、CD68、I型胶原蛋白水平升高;肝脏病变标志物升高导致功能改变;通过改变白细胞,淋巴细胞和血小板。最后,在纤维性肝中检测移植细胞。我们得出结论,采用本研究介绍的方案应用TAA可诱导大鼠晚期肝纤维化的良好模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Analytical Cellular Pathology
Analytical Cellular Pathology ONCOLOGY-CELL BIOLOGY
CiteScore
4.90
自引率
3.10%
发文量
70
审稿时长
16 weeks
期刊介绍: Analytical Cellular Pathology is a peer-reviewed, Open Access journal that provides a forum for scientists, medical practitioners and pathologists working in the area of cellular pathology. The journal publishes original research articles, review articles, and clinical studies related to cytology, carcinogenesis, cell receptors, biomarkers, diagnostic pathology, immunopathology, and hematology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信